EUVIMEDEUVIMED entdecken
Randomisierte kontrollierte StudieMultizentrische StudieKlinische Studie (Phase II)

A Phase 2 Randomized Trial of Mezagitamab in Primary Immune Thrombocytopenia

David J Kuter, Katsuhiro Miura, Andrea Patriarca, Dražen Pulanić, Atanas Radinoff, Katya Sapunarova, Antonia Syrigou, Renchi Yang, Van Anh Nguyen, Emily Skelton, Scarlett Wang, Donald L Yee und 2 weitere

New England Journal of Medicine · 09.04.2026 · 394 (14) · 1388-1398

DOI: 10.1056/nejmoa2513120 ↗

Kurz gefasst

Randomisierte kontrollierte Studie in der Zeitschrift New England Journal of Medicine, erschienen am 09.04.2026. Verfasst von David J Kuter und 13 weiteren Autor:innen. Beteiligte Einrichtung: Hematology Division, Massachusetts General Hospital, Boston. Hauptthemen laut MEDLINE: Antibodies, Monoclonal, Humanized, Purpura, Thrombocytopenic, Idiopathic, ADP-ribosyl Cyclase 1, Membrane Glycoproteins. Die Arbeit wurde bisher 8-mal zitiert (Crossref) und nennt 31 Literaturangaben. Gefördert von: Takeda Development Center Americas, Inc..

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Kein Abstract verfügbar.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Antibodies, Monoclonal, HumanizedPurpura, Thrombocytopenic, IdiopathicADP-ribosyl Cyclase 1Membrane GlycoproteinsAdultAgedFemaleHumansMaleMiddle AgedYoung AdultDouble-Blind MethodInjections, SubcutaneousPlatelet CountDrugs, InvestigationalAged, 80 and overTreatment Outcome

Substanzen

Antibodies, Monoclonal, HumanizedDrugs, InvestigationalCD38 protein, humanADP-ribosyl Cyclase 1Membrane Glycoproteins

Autor:innen und Institutionen

  • Hematology Division, Massachusetts General Hospital, Boston.
  • Harvard Medical School, Boston.
  • Division of Hematology and Rheumatology, Department of Medicine, Nihon University School of Medicine, Tokyo.
  • Therapeutic Innovation in Hematology, Hematology Unit, Azienda Ospedaliero-Universitaria Maggiore della Carità, Novara, Italy.
  • Department of Translational Medicine, University of Eastern Piedmont, Novara, Italy.
  • Division of Hematology, Department of Internal Medicine, University Hospital Center Zagreb, Zagreb, Croatia.

Förderung

  • Takeda Development Center Americas, Inc.

Zitieren

APA

Kuter, D. J., Miura, K., Patriarca, A., Pulanić, D., Radinoff, A., Sapunarova, K., Syrigou, A., Yang, R., Nguyen, V. A., Skelton, E., Wang, S., Yee, D. L., Patwari, P., & Mezagitamab ITP Phase 2 Trial Investigators (2026). A Phase 2 Randomized Trial of Mezagitamab in Primary Immune Thrombocytopenia. New England Journal of Medicine, 394(14), 1388-1398. https://doi.org/10.1056/nejmoa2513120

Vancouver

Kuter DJ, Miura K, Patriarca A, Pulanić D, Radinoff A, Sapunarova K, et al. A Phase 2 Randomized Trial of Mezagitamab in Primary Immune Thrombocytopenia. New England Journal of Medicine. 2026;394(14):1388-1398. doi:10.1056/nejmoa2513120

BibTeX
@article{Kuter2026,
  author = {Kuter, David J and Miura, Katsuhiro and Patriarca, Andrea and Pulanić, Dražen and Radinoff, Atanas and Sapunarova, Katya and Syrigou, Antonia and Yang, Renchi and Nguyen, Van Anh and Skelton, Emily and Wang, Scarlett and Yee, Donald L and Patwari, Parth and Mezagitamab ITP Phase 2 Trial Investigators, Mezagitamab ITP Phase 2 Trial Investigators},
  title = {A Phase 2 Randomized Trial of Mezagitamab in Primary Immune Thrombocytopenia},
  journal = {New England Journal of Medicine},
  year = {2026},
  volume = {394},
  number = {14},
  pages = {1388--1398},
  doi = {10.1056/nejmoa2513120}
}
Kostenlos starten →